Concord Biotech Ltd
NSE:CONCORDBIO
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 366.65
2 601.1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Concord Biotech Ltd
Net Issuance of Debt
Concord Biotech Ltd
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Concord Biotech Ltd
NSE:CONCORDBIO
|
Net Issuance of Debt
-₹265m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Net Issuance of Debt
₹32.7B
|
CAGR 3-Years
143%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Net Issuance of Debt
-₹5.7B
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Net Issuance of Debt
₹4.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Net Issuance of Debt
-₹13.9B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Net Issuance of Debt
₹314.4m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Concord Biotech Ltd
Glance View
Nestled in the vibrant landscape of the Indian pharmaceutical industry, Concord Biotech Ltd. has woven itself into the intricate fabric of global healthcare solutions. Founded in 2000, the company has carved a niche for itself by becoming a leading manufacturer of fermentation-based biopharmaceutical APIs (Active Pharmaceutical Ingredients). Its core strength lies in developing recombinant APIs and fermentation-based life-saving drugs, establishing a robust pipeline that caters to the therapeutic needs of oncology, immunology, and infectious diseases. Concord Biotech's state-of-the-art manufacturing facilities adhere to stringent international standards, including approvals from USFDA and EUGMP, enabling the company to establish a significant presence in markets across the globe. The company's revenue model thrives on the optimized production of high-demand biotech APIs, synergizing innovation with commercial viability. By partnering with global pharmaceutical giants, Concord Biotech boosts the formulation and development of finished dosage forms, leveraging its cutting-edge research and development capabilities. The firm taps into economies of scale via partnerships and strategic alliances, which allow it to competitively price its offerings while maintaining robust profit margins. Moreover, the company continually invests in expanding its product portfolio and production capacities, ensuring sustainable growth and a strong market position in the ever-evolving pharmaceutical landscape. Through a combination of technological prowess and market insight, Concord Biotech Ltd. paves its path as a cornerstone in the global pharmaceutical supply chain.
See Also
What is Concord Biotech Ltd's Net Issuance of Debt?
Net Issuance of Debt
-265m
INR
Based on the financial report for Mar 31, 2024, Concord Biotech Ltd's Net Issuance of Debt amounts to -265m INR.
What is Concord Biotech Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 1Y
1%
Over the last year, the Net Issuance of Debt growth was 1%.
You don't have any saved screeners yet
